Selective 20S proteasomal inhibition and apoptosis induction were observed when several lines of cancer cells were treated with a series of copper complexes described as [Cu(L(I))Cl] (1), [Cu(L(I))OAc] (2), and [Cu(HL(I))(L(I))]OAc (3), where HL(I) is the ligand 2,4-diiodo-6-((pyridine-2-ylmethylamino)methyl)phenol. These complexes were synthesized, characterized by means of ESI spectrometry, infrared, UV-visible and EPR spectroscopies, and X-ray diffraction when possible. After full characterization species 1-3 were evaluated for their ability to function as proteasome inhibitors and apoptosis inducers in C4-2B and PC-3 human prostate cancer cells and MCF-10A normal cells. With distinct stoichiometries and protonation states, this series suggests the assignment of species [CuL(I)](+) as the minimal pharmacophore needed for proteasomal chymotryspin-like activity inhibition and permits some initial inference of mechanistic information.
Selective 20S proteasomal inhibition and apoptosis induction were observed when several lines of cancer cells were treated with a series of n class="Chemical">copper complexes described as [Cu(L(I))Cl] (1), [Cu(L(I))OAc] (2), and [Cu(HL(I))(L(I))]OAc (3), where HL(I) is the ligand 2,4-diiodo-6-((pyridine-2-ylmethylamino)methyl)phenol. These complexes were synthesized, characterized by means of ESI spectrometry, infrared, UV-visible and EPR spectroscopies, and X-ray diffraction when possible. After full characterization species 1-3 were evaluated for their ability to function as proteasome inhibitors and apoptosis inducers in C4-2B and PC-3humanprostate cancer cells and MCF-10A normal cells. With distinct stoichiometries and protonation states, this series suggests the assignment of species [CuL(I)](+) as the minimal pharmacophore needed for proteasomal chymotryspin-like activity inhibition and permits some initial inference of mechanistic information.
Authors: Jason Labutti; Ian Parsons; Ron Huang; Gerald Miwa; Liang-Shang Gan; J Scott Daniels Journal: Chem Res Toxicol Date: 2006-04 Impact factor: 3.739
Authors: Teru Hideshima; Constantine Mitsiades; Masaharu Akiyama; Toshiaki Hayashi; Dharminder Chauhan; Paul Richardson; Robert Schlossman; Klaus Podar; Nikhil C Munshi; Nicholas Mitsiades; Kenneth C Anderson Journal: Blood Date: 2002-09-26 Impact factor: 22.113
Authors: Kenyon G Daniel; Di Chen; Shirley Orlu; Qiuzhi Cindy Cui; Fred R Miller; Q Ping Dou Journal: Breast Cancer Res Date: 2005-09-20 Impact factor: 6.466
Authors: Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou Journal: Curr Pharm Des Date: 2010-06 Impact factor: 3.116
Authors: G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta Journal: Pharmacol Ther Date: 2020-05-19 Impact factor: 12.310
Authors: Michael Frezza; Sarmad Sahiel Hindo; Dajena Tomco; Marco M Allard; Qiuzhi Cindy Cui; Mary Jane Heeg; Di Chen; Q Ping Dou; Cláudio N Verani Journal: Inorg Chem Date: 2009-07-06 Impact factor: 5.165
Authors: Kirill K Geyl; Sergey V Baykov; Stanislav A Kalinin; Alexandr S Bunev; Marina A Troshina; Tatiana V Sharonova; Mikhail Yu Skripkin; Svetlana O Kasatkina; Sofia I Presnukhina; Anton A Shetnev; Mikhail Yu Krasavin; Vadim P Boyarskiy Journal: Biomedicines Date: 2022-02-16